Laurel Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 28-06-2024
- Paid Up Capital ₹ 0.45 M
as on 28-06-2024
- Company Age 43 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.55 M
as on 28-06-2024
- Revenue -11.17%
(FY 2023)
- Profit -2.50%
(FY 2023)
- Ebitda -9.15%
(FY 2023)
- Net Worth 16.04%
(FY 2023)
- Total Assets -7.95%
(FY 2023)
About Laurel Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.45 M.
The company currently has active open charges totaling ₹2.55 M.
Udit Nanda, Sunita Nanda, and Ajay Nanda serve as directors at the Company.
- CIN/LLPIN
U24232PB1981PTC004609
- Company No.
004609
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Jul 1981
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Jalandhar, Punjab, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Laurel Pharmaceuticals Pvt Ltd offer?
Laurel Pharmaceuticals Pvt Ltd offers a wide range of products and services, including Common Disease Medicines, Herbal Cough Syrup.
Who are the key members and board of directors at Laurel Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Udit Nanda  | Director | 27-Jul-2010 | Current |
| Sunita Nanda | Director | 27-Jul-2010 | Current |
| Ajay Nanda | Director | 25-Aug-1982 | Current |
Financial Performance of Laurel Pharmaceuticals.
Laurel Pharmaceuticals Pvt Ltd, for the financial year ended 2023, experienced significant reduction in revenue, with a 11.17% decrease. The company also saw a slight decrease in profitability, with a 2.5% decrease in profit. The company's net worth Soared by an impressive increase of 16.04%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Laurel Pharmaceuticals?
Unlock access to Laurel Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 12 Feb 2018 | ₹0.60 M | Open |
Canara Bank Creation Date: 09 May 2011 | ₹0.11 M | Open |
Canara Bank Creation Date: 11 Dec 1996 | ₹0.32 M | Open |
How Many Employees Work at Laurel Pharmaceuticals?
Laurel Pharmaceuticals has a workforce of 3 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Laurel Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Laurel Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
